KATIE MONTGOMERY: Open Payments
NPI 1841845286 · CORPUS CHRISTI, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,151 in 55 payments from 18 companies in 2025. Trend: 2023 $16,764 · 2024 $1,103 · 2025 $2,151
Food & beverage: $2,151
| Company | Payments | Amount |
|---|---|---|
| Bayer Healthcare Pharmaceuticals Inc. | 11 | $409 |
| AstraZeneca Pharmaceuticals LP | 9 | $381 |
| Amgen Inc. | 5 | $283 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 8 | $250 |
| Novo Nordisk Inc | 2 | $150 |
| Dexcom, Inc. | 1 | $122 |
| GENZYME CORPORATION | 1 | $103 |
| AKEBIA THERAPEUTICS INC | 1 | $86 |
| Calliditas Therapeutics US Inc. | 4 | $81 |
| Xeris Pharmaceuticals, Inc. | 3 | $69 |
Products named: Kerendia, JARDIANCE, FARXIGA, KRYSTEXXA, Wegovy, TAVNEOS, DEXCOM G7 GSS (161), FABRAZYME.
Industry payments across TX — which companies pay providers there.
